Ardelyx, Inc. (ARDX): R&D Expense
$71.53M
Year ended 2025-12-31
$87.21M
Trailing 12 months to 2026-06-30
+26.7%
3-year compound annual growth
+1.9%
5-year compound annual growth
+6.0%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.53M | +36.7% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $52.32M | +47.2% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $35.54M | +1.0% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $35.20M | -61.4% | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | $91.14M | +40.1% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $65.05M | -9.2% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $71.68M | +3.3% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $69.37M | -8.1% | 2021-03-08, From 2018-01-01 |
| 2017-12-31 | $75.48M | -19.8% | 2020-03-06, From 2017-01-01 |
| 2016-12-31 | $94.16M | +136.1% | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | $39.88M | +54.0% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $25.90M | -7.8% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $28.09M | +175.9% | 2016-03-04, From 2013-01-01 |
| 2012-12-31 | $10.18M | n/a | 2015-03-05, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $71.53M | +36.7% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $30.60M | +124.1% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $216.18M | -20.1% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $77.05M | +0.8% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $220.90M | -5.8% |
| MannKind Corp (MNKD) | 2025-12-31 | $66.35M | +44.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $206.01M | -5.3% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $451.95M | -10.8% |
Compare ARDX, INVA, SVA, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗